No Data
Kyodo Pharmaceutical: 2024 Annual Results Forecast
Pacific Securities: Q3 revenue and profit growth of the active pharmaceutical ingredient sector have accelerated significantly, bullish on the high growth trend in Q4 performance.
In Q1 2024, the gross margin of the sector was 36.38%, with a net margin of 12.78%. In Q2, the gross margin was 37.21%, with a net margin of 15.52%. In Q3, the gross margin was 38.27%, +1.88pct year-on-year, +1.06pct quarter-on-quarter, with a net margin of 14.07%, +3.98pct year-on-year, -1.45pct quarter-on-quarter, both gross margin and net margin reaching a new high compared to the same period in the past three years.
Jointown Pharmaceutical (300966.SZ): Currently, the company's business has not yet entered the AI field.
Gelonghui November 6th | Joint Pharmaceutical (300966.SZ) stated on the investor interaction platform that the current business of the company has not yet involved the AI field, and the company will carefully consider it in future development.
Kyodo Pharmaceutical: Third quarter report 2024
Jointown Pharma (300966.SZ): The net loss in the third quarter was 9.0436 million yuan.
On October 23, GeLongHui announced the third quarter report for 2024, with operating revenue of 0.132 billion yuan, a year-on-year increase of 12.24%; net income attributable to shareholders of listed companies -9.0436 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses -9.8436 million yuan; basic earnings per share -0.08 yuan.
Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Share Price Boosted 42% But Its Business Prospects Need A Lift Too
Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
